132 related articles for article (PubMed ID: 19629392)
1. New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.
Santucci MA; Mancini M; Corradi V; Lacobucci I; Martinelli G; Botta M; Schenone S
Invest New Drugs; 2010 Dec; 28(6):876-8. PubMed ID: 19629392
[No Abstract] [Full Text] [Related]
2. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Nguyen TK; Rahmani M; Harada H; Dent P; Grant S
Blood; 2007 May; 109(9):4006-15. PubMed ID: 17218385
[TBL] [Abstract][Full Text] [Related]
3. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
4. An update on dual Src/Abl inhibitors.
Musumeci F; Schenone S; Brullo C; Botta M
Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.
Lu XY; Cai Q; Ding K
Curr Med Chem; 2011; 18(14):2146-57. PubMed ID: 21517764
[TBL] [Abstract][Full Text] [Related]
8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
9. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
10. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
O'Hare T; Eide CA; Deininger MW
Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
[TBL] [Abstract][Full Text] [Related]
11. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
[TBL] [Abstract][Full Text] [Related]
12. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
13. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
[TBL] [Abstract][Full Text] [Related]
14. Bcr-Abl tyrosine kinase inhibitors: a patent review.
Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
[TBL] [Abstract][Full Text] [Related]
15. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M
ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816
[TBL] [Abstract][Full Text] [Related]
16. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
17. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms.
Schenone S; Brullo C; Botta M
Curr Med Chem; 2010; 17(13):1220-45. PubMed ID: 20166937
[TBL] [Abstract][Full Text] [Related]
18. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.
Eiring AM; Deininger MW
Genome Biol; 2014 Sep; 15(9):461. PubMed ID: 25316524
[TBL] [Abstract][Full Text] [Related]
19. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
O'Hare T; Walters DK; Stoffregen EP; Sherbenou DW; Heinrich MC; Deininger MW; Druker BJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6987-93. PubMed ID: 16203792
[TBL] [Abstract][Full Text] [Related]
20. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
